Education
About Us
Working with TipRanks
Follow Us
Journey Medical Corp (DERM)
NASDAQ:DERM
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.24Last Year’s EPS
-0.53Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 26, 2025
|% Change Since: 1.79%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with significant achievements, including the FDA approval and upcoming launch of MROSI, positive EBITDA, and a strong cash position. However, there are challenges with decreased revenue from legacy products and increased R&D expenses. The sentiment is buoyed by the transformational potential of MROSI and its expected market impact.Company Guidance
In the 2024 financial update call, Journey Medical highlighted several key metrics and strategic achievements. The company reported annual revenue of $56 million and successfully met all financial guidance ranges for the year. The fourth quarter marked the sixth consecutive quarter of positive non-GAAP adjusted EBITDA. Journey Medical launched MROSI, an oral treatment for rosacea, after receiving FDA approval in November 2024. Despite paying $22 million in FDA filing fees and milestone payments to Dr. Reddy Labs, the company maintained a strong balance sheet with $20.3 million in cash as of December 31, 2024. MROSI's market entry positions Journey Medical in a $1 billion-plus treatment category, with expectations of significant operating leverage and potential peak annual sales of $200 million in the United States. The company achieved approximately 20% commercial payer coverage for MROSI and plans to expand this coverage throughout 2025. Journey Medical also reported a net loss of $14.7 million for 2024, compared to a net loss of $3.9 million in 2023. The positive momentum from 2024 is expected to continue into 2025, with several strategic initiatives, including increased payer coverage and additional peer-reviewed publications, aimed at driving growth and shareholder value.MROSI FDA Approval and Launch
MROSI received on-time first cycle FDA approval in November 2024, with the launch set for early April 2025. This is Journey Medical's first internally developed asset, expected to become a major growth driver with potential peak annual sales of $200 million in the U.S. and $100 million internationally.
Positive Non-GAAP Adjusted EBITDA
The fourth quarter of 2024 marked the sixth consecutive quarter with a positive non-GAAP adjusted EBITDA, totaling $800,000 for the year.
Strong Cash Position
Journey Medical ended 2024 with $20.3 million in cash, maintaining a strong balance sheet despite significant FDA filing fees and milestone payments.
Successful Presence at Medical Conferences
MROSI's clinical data were presented at key medical congresses, garnering significant interest, and the Phase 3 results were published in JAMA Dermatology.
---
DERM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DERM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 26, 2025 | $6.14 | $5.92 | -3.58% |
| Nov 12, 2024 | $5.45 | $5.12 | -6.06% |
| Aug 12, 2024 | $4.22 | $4.82 | +14.22% |
| May 13, 2024 | $3.57 | $3.61 | +1.12% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Journey Medical Corp (DERM) report earnings?
Journey Medical Corp (DERM) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Journey Medical Corp (DERM) earnings time?
Journey Medical Corp (DERM) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DERM EPS forecast?
DERM EPS forecast for the fiscal quarter 2025 (Q1) is -0.24.
---